Invesco LLC Sells 988 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Invesco LLC reduced its holdings in Thermo Fisher Scientific by 8.9% in the second quarter, now owning 10,168 shares worth approximately $4.12 million.
• The company reported an EPS of $5.36 for the last quarter, exceeding analysts' expectations, along with a revenue of $10.86 billion.
• Thermo Fisher announced a quarterly dividend of $0.43 per share, representing an annualized dividend yield of 0.4% and a payout ratio of 9.95%.

Invesco LLC trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 8.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,168 shares of the medical research company's stock after selling 988 shares during the period. Thermo Fisher Scientific comprises approximately 1.5% of Invesco LLC's investment portfolio, making the stock its 14th largest holding. Invesco LLC's holdings in Thermo Fisher Scientific were worth $4,123,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Revolve Wealth Partners LLC boosted its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after purchasing an additional 20 shares during the period. Intergy Private Wealth LLC raised its stake in Thermo Fisher Scientific by 5.8% in the first quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock valued at $208,000 after purchasing an additional 23 shares in the last quarter. Root Financial Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 5.0% during the 1st quarter. Root Financial Partners LLC now owns 506 shares of the medical research company's stock worth $252,000 after acquiring an additional 24 shares during the last quarter. Rossmore Private Capital boosted its holdings in shares of Thermo Fisher Scientific by 0.5% in the 1st quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company's stock worth $2,315,000 after purchasing an additional 24 shares in the last quarter. Finally, FARMERS & MERCHANTS TRUST Co OF LONG BEACH grew its position in Thermo Fisher Scientific by 3.1% during the second quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company's stock valued at $326,000 after acquiring an additional 24 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Trading Up 1.1%

NYSE TMO opened at $464.18 on Monday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $623.77. The company has a 50 day moving average price of $476.70 and a 200 day moving average price of $447.15. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The firm has a market cap of $175.28 billion, a PE ratio of 26.85, a price-to-earnings-growth ratio of 2.52 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same period last year, the business earned $5.37 EPS. Thermo Fisher Scientific's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Insider Activity at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of analyst reports. William Blair assumed coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an "outperform" rating for the company. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Raymond James Financial reissued an "outperform" rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the stock an "outperform" rating in a research report on Tuesday, September 2nd. Finally, Barclays upgraded shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $490.00 to $550.00 in a research report on Thursday, September 11th. Sixteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $588.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.